Biofrontera Inc. Warrants financials
$0.0135−32.50%
Close Sep 28, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $41.7M | $37.3M | $34.1M | $28.7M | $24.1M |
| Gross profit | $30.7M | $18.7M | $16.6M | $13.5M | $11.4M |
| Gross margin | 73.7% | 50.1% | 48.8% | 47.0% | 47.1% |
| Operating income | -$11.3M | -$17.2M | -$22.7M | -$18.6M | -$25.2M |
| Net income | -$10.5M | -$17.8M | -$20.1M | -$640.0K | -$37.7M |
| Net margin | −25.3% | −47.6% | −59.1% | −2.2% | −156.5% |
| Diluted EPS | $-1.04 | $-3.22 | $-13.02 | $-0.61 | $-85.60 |
| EBITDA | -$11.2M | -$16.8M | -$22.2M | -$21.2M | -$25.3M |
| Operating cash flow | -$13.4M | -$10.3M | -$24.9M | -$16.2M | -$25.3M |
| Free cash flow | -$13.4M | -$10.3M | -$24.9M | -$16.2M | — |
| Diluted shares | 10.2M | 5.5M | 1.5M | 1.1M | 0.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $6.4M | $5.9M | $1.3M | $17.2M | $24.5M |
| Short-term investments | $9.0K | $7.0K | $0.00 | $0.00 | $0.00 |
| Total debt | $4.6M | $4.1M | $3.9M | $0.00 | $0.00 |
| Total assets | $28.6M | $22.1M | $27.9M | $50.9M | $53.2M |
| Total liabilities | $18.1M | $17.7M | $23.1M | $27.0M | $41.9M |
| Shareholders' equity | $10.5M | $4.4M | $4.8M | $23.9M | $11.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology